Trials / Unknown
UnknownNCT04603833
A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC
A Phase II Clinical Study of SHR3680 Combined With Docetaxel in the Treatment of Metastatic Castration-resistant Prostate Cancer Previously Treated With Abiraterone
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this trial is to evaluate SHR3680 combined with Docetaxel to improve Metastatic Castration Resistant Prostate Cancer Patients whether the patient's Time to prostate specific antigen (PSA) progression is superior to SHR3680 or Docetaxel single drug.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR3680+Docetaxel | Participants will receive SHR3680 combined with Docetaxel |
| DRUG | SHR3680 | Participants will receive SHR3680 |
| DRUG | Docetaxel | Participants will receive Docetaxel |
Timeline
- Start date
- 2020-12-02
- Primary completion
- 2022-10-01
- Completion
- 2022-12-31
- First posted
- 2020-10-27
- Last updated
- 2021-02-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04603833. Inclusion in this directory is not an endorsement.